Kirill Aleksandrovich Borzov
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Kirill Aleksandrovich Borzov has a total of 55 co-authors. Here are the top co-authors by number of shared publications:
- Aslan Kamraddinovich Valiev
N.N. Blokhin National Medical Research Center of Oncology, Ministry of Health of Russia
7 shared publications - Denis I. Sofronov
N.N. Blokhin National Medical Research Center of Oncology, 115478 Moscow, Russia
5 shared publications - Ruslan Magomedovich Kabardaev
N.N. Blokhin National Medical Research Center of Oncology, Ministry of Health of Russia
4 shared publications - Evgeny A. Sushentsov
N.N. Blokhin National Medical Research Center of Oncology, Ministry of Health of Russia
3 shared publications - A. M. Galustov
N.N. Blokhin National Medical Research Center of Oncology, Ministry of Health of Russia
2 shared publications - Aleksandr Aleksandrovich Fedenko
P.A. Hertzen Moscow Oncology Research Institute – branch of the National Medical Research Radiological Center, Ministry of Health of Russia
2 shared publications
Latest Publications
- 26 June 2026
- Published by Publishing House ABV Press in Supportive Therapy in Oncology
- Vol. 3 (1) , 35-42
Parenteral form of ibuprofen for pain relief in the early postoperative period in cancer patients after thoracoscopic and bone-plastic surgery
Aim. То compare the safety of use and the analgesic effect of postoperative anesthesia regimens using non-steroidal anti-inflammatory drug (NSAID) – Intrafen-GEN (ibuprofen) with a scheme of postoperative anesthesia based on narcotic analgesics in oncological patients after thoracoscopic and bone-plastic surgery. To evaluate the possibilities of using a postoperative anesthesia regimen using NSAIDs – Intrafen-GEN (ibuprofen) within the framework of the ERAS protocol (Enhanced Recovery After Surgery). Materials and methods. A single-center prospective comparative study conducted at the N.N. Trapeznikov Research Institute of Clinical Oncology in 2024–2025 included 98 patients who underwent minimally invasive thoracic and bone-plastic surgery. Results. Based on the area of surgical intervention, all patients (n=98) were divided first into 2 groups, and then into subgroups A and B, according to the schemes of postoperative anesthesia. The first group included 64 patients. It was divided into subgroups A (n = 34) and B (n = 30). The second group included 34 patients and was also divided into subgroups A and B with an equal number of patients in each of the subgroups (n = 17). Patients in subgroup A received a postoperative pain relief regimen using Intrafen-GEN (ibuprofen), and patients in subgroup B received a regimen using trimeperidine. The first intravenous dose of Intrafen-GEN (ibuprofen) – 800 mg was administered 30 minutes before the end of surgery or immediately upon admission to the intensive care unit, then every 8–12 hours for 3 days. In the case of persistent pain, non-opioid and opioid analgesics were added to the treatment until the pain completely disappeared. Patients in subgroup B received anesthesia with trimeperidine 20 mg intramuscularly every 8 hours for 3 postoperative days. The quality of anesthesia in the postoperative period was assessed using the visual analog scale. Conclusion. In our study, Intrafen-GEN (ibuprofen) was found to be a safe drug, as no complications or side effects were observed during its use. The pain management regimens based on Intrafen-GEN (ibuprofen) demonstrated the complete elimination of opioid analgesics from postoperative pain management in 24 (70.59 %) patients after thoracoscopic surgeries and in 10 (58.85 %) patients after bone-plastic surgeries. When using Intrafen-GEN (ibuprofen), there are no contraindications for the ERAS protocol and early activation of patients in the ICU.
- 26 June 2026
- Published by Publishing House ABV Press in Supportive Therapy in Oncology
- Vol. 3 (1) , 35-42
Parenteral form of ibuprofen for pain relief in the early postoperative period in cancer patients after thoracoscopic and bone-plastic surgery
Aim. То compare the safety of use and the analgesic effect of postoperative anesthesia regimens using non-steroidal anti-inflammatory drug (NSAID) – Intrafen-GEN (ibuprofen) with a scheme of postoperative anesthesia based on narcotic analgesics in oncological patients after thoracoscopic and bone-plastic surgery. To evaluate the possibilities of using a postoperative anesthesia regimen using NSAIDs – Intrafen-GEN (ibuprofen) within the framework of the ERAS protocol (Enhanced Recovery After Surgery). Materials and methods. A single-center prospective comparative study conducted at the N.N. Trapeznikov Research Institute of Clinical Oncology in 2024–2025 included 98 patients who underwent minimally invasive thoracic and bone-plastic surgery. Results. Based on the area of surgical intervention, all patients (n=98) were divided first into 2 groups, and then into subgroups A and B, according to the schemes of postoperative anesthesia. The first group included 64 patients. It was divided into subgroups A (n = 34) and B (n = 30). The second group included 34 patients and was also divided into subgroups A and B with an equal number of patients in each of the subgroups (n = 17). Patients in subgroup A received a postoperative pain relief regimen using Intrafen-GEN (ibuprofen), and patients in subgroup B received a regimen using trimeperidine. The first intravenous dose of Intrafen-GEN (ibuprofen) – 800 mg was administered 30 minutes before the end of surgery or immediately upon admission to the intensive care unit, then every 8–12 hours for 3 days. In the case of persistent pain, non-opioid and opioid analgesics were added to the treatment until the pain completely disappeared. Patients in subgroup B received anesthesia with trimeperidine 20 mg intramuscularly every 8 hours for 3 postoperative days. The quality of anesthesia in the postoperative period was assessed using the visual analog scale. Conclusion. In our study, Intrafen-GEN (ibuprofen) was found to be a safe drug, as no complications or side effects were observed during its use. The pain management regimens based on Intrafen-GEN (ibuprofen) demonstrated the complete elimination of opioid analgesics from postoperative pain management in 24 (70.59 %) patients after thoracoscopic surgeries and in 10 (58.85 %) patients after bone-plastic surgeries. When using Intrafen-GEN (ibuprofen), there are no contraindications for the ERAS protocol and early activation of patients in the ICU.
- Open Access
- 25 July 2025
- Published by Publishing House ABV Press in Bone and soft tissue sarcomas, tumors of the skin
- Vol. 17 (2) , 47-59
Surgical treatment of patients with pelvic bone metastases
Introduction. Pelvic bone metastases are a common complication of malignant tumors, leading to pain, pathological fractures, and decreased quality of life. Surgical treatment plays a key role in palliative care, but the optimal approaches remain controversial.Aim. To evaluate the results of surgical treatment of patients with pelvic bone metastases, including oncologic and functional outcomes, as well as complication rates.Materials and methods. A retrospective analysis of 39 patients (21 men, 18 women; median age 55 years) who underwent surgical treatment for metastatic pelvic bone lesions in the period 2002–2022 was performed. The most common localizations were the ilium (10 (25.6 %) cases) and sacrum (13 (33.3 %) cases). A solitary lesion was detected in 33 (84.6 %) patients and multiple bone lesions in 6 (5.4 %) patients. The primary lesion in most cases (in 19 (48.7 %) patients) was kidney cancer. Radical (wide resections) (71.8 % cases) and palliative (decompression and excohleations) (23.1 % cases) methods were used. Survival, complications (according to the Clavien–Dindo classification), pain dynamics (according to the visual analog and Watkins scales) and functional status (according to the Karnofsky scale) were assessed.Results. Complications developed in 28.2 % of patients, mainly after resections involving the acetabulum (p = 0.029). The leading complications were deep infections (8 cases), superficial necrosis (3 cases), which required additional surgical interventions. The median overall survival was 45 months, with solitary metastases – 93 months, with multiple metastases – 20 months (p = 0.019). Intralesional resections were associated with worse survival (p = 0.028). A significant decrease in pain (from 5 to 2 according to the visual analog scale; p 0.001) and improvement in functional status (according to the Karnofsky scale; p = 0.022) were noted. Conclusion. Radical resections provide better survival in solitary metastases group, while palliative methods are appropriate for multiple lesions. The choice of tactics requires a multidisciplinary approach, taking into account the prognosis and extent of the lesion.
- 25 July 2025
- Published by Publishing House ABV Press in Bone and soft tissue sarcomas, tumors of the skin
- Vol. 17 (2) , 47-59
Open AccessSurgical treatment of patients with pelvic bone metastases
Introduction. Pelvic bone metastases are a common complication of malignant tumors, leading to pain, pathological fractures, and decreased quality of life. Surgical treatment plays a key role in palliative care, but the optimal approaches remain controversial.Aim. To evaluate the results of surgical treatment of patients with pelvic bone metastases, including oncologic and functional outcomes, as well as complication rates.Materials and methods. A retrospective analysis of 39 patients (21 men, 18 women; median age 55 years) who underwent surgical treatment for metastatic pelvic bone lesions in the period 2002–2022 was performed. The most common localizations were the ilium (10 (25.6 %) cases) and sacrum (13 (33.3 %) cases). A solitary lesion was detected in 33 (84.6 %) patients and multiple bone lesions in 6 (5.4 %) patients. The primary lesion in most cases (in 19 (48.7 %) patients) was kidney cancer. Radical (wide resections) (71.8 % cases) and palliative (decompression and excohleations) (23.1 % cases) methods were used. Survival, complications (according to the Clavien–Dindo classification), pain dynamics (according to the visual analog and Watkins scales) and functional status (according to the Karnofsky scale) were assessed.Results. Complications developed in 28.2 % of patients, mainly after resections involving the acetabulum (p = 0.029). The leading complications were deep infections (8 cases), superficial necrosis (3 cases), which required additional surgical interventions. The median overall survival was 45 months, with solitary metastases – 93 months, with multiple metastases – 20 months (p = 0.019). Intralesional resections were associated with worse survival (p = 0.028). A significant decrease in pain (from 5 to 2 according to the visual analog scale; p 0.001) and improvement in functional status (according to the Karnofsky scale; p = 0.022) were noted. Conclusion. Radical resections provide better survival in solitary metastases group, while palliative methods are appropriate for multiple lesions. The choice of tactics requires a multidisciplinary approach, taking into account the prognosis and extent of the lesion.
- 17 April 2025
- Published by Publishing House ABV Press in Bone and soft tissue sarcomas, tumors of the skin
- Vol. 17 (1)
The first experience of total sacral endoprothesis with an individual implant after total sacrectomy (a rare clinical case)
Bone sarcomas are one the rarest types of malignant tumors comprising only 0.2–1 % of oncological diseases. Chondrosarcoma is the 3rd most common bone sarcoma. This tumor is characterized by low sensitivity to drug and radiological treatment. According to literature data, the current golden standard of bone chondrosarcoma treatment is en bloc radical surgical resection with preservation of clean resection margins. However, common for this tumor location in the pelvic bones can pose difficulties at the stage of surgical planning.The article presents a clinical case of surgical treatment of sacrum G2 chondrosarcoma in the volume of total sacrectomy with defect replacement using a personalized implant manufactured using a 3D printer and with lumbosacral stabilization.
- 17 April 2025
- Published by Publishing House ABV Press in Bone and soft tissue sarcomas, tumors of the skin
- Vol. 17 (1)
The first experience of total sacral endoprothesis with an individual implant after total sacrectomy (a rare clinical case)
Bone sarcomas are one the rarest types of malignant tumors comprising only 0.2–1 % of oncological diseases. Chondrosarcoma is the 3rd most common bone sarcoma. This tumor is characterized by low sensitivity to drug and radiological treatment. According to literature data, the current golden standard of bone chondrosarcoma treatment is en bloc radical surgical resection with preservation of clean resection margins. However, common for this tumor location in the pelvic bones can pose difficulties at the stage of surgical planning.The article presents a clinical case of surgical treatment of sacrum G2 chondrosarcoma in the volume of total sacrectomy with defect replacement using a personalized implant manufactured using a 3D printer and with lumbosacral stabilization.
- Open Access
- 18 December 2024
- Published by Consilium Medicum in Journal of Modern Oncology
- Vol. 26 (4) , 495-503
Pain relief clinical efficacy using pulsed radiofrequency ablation of nerve roots in patients with spine metastatic lesions. A prospective study
Aim. The objective of the study is to evaluate the clinical efficacy and safety of PRFA (pulsed radiofrequency ablation) of nerve roots in improving general somatic and functional status (Karnofsky score), decreasing pain (NRS) and reducing analgesics consumption (Watkins score) in patients with spine metastatic lesions. Materials and methods. This study involved the analysis of 230 patients with pain syndrome related to metastatic lesions in the spine. Those patients were divided into two groups. The first group included 156 patients who underwent Pulsed RFA of nerve roots in order to relieve pain. There were 69 men and 87 women. The second group, which received only drug treatment with non-opioid and opioid analgesics, consisted of 74 patients, including 30 men and 44 women. The performance status was evaluated with the Karnofsky score (%), pain degree was assessed with the Numerical Rating Scale from 0 to 10 (NRS), and analgesics consumption reduction was assessed by the Watkins scale. Overall treatment satisfaction in patients and physicians was evaluated with the Likert scale. Results. In the pulsed RFA group, 124 (79.5%) patients out of 156 had effective therapy in the form of NRS decrease of at least 50% and at least 1 point decrease by the Watkins scale. The performance status improved by at least 10% according to the Karnofsky index in 121 (77.6%) patients. As for the control group, the effectiveness of pharmacotherapy based on NRS was achieved in 65 (87.8%) out of 74 patients, and the general somatic status was improved in 60 (81.1%) patients. The maximum analgesic effect of the nerve root RFA is achieved on the 10th day after the procedure, maintaining for up to 90 days without dynamics. The level of statistical significance was p0.001. In the RFA group, 153 (98.01%) patients experienced no complications, and in the control group, complications were seen in 64 (86.5%) cases, manifested themselves in the form of adverse events from analgesics used for pain control. Originally, prior to the study, all 100% of patients in both groups expressed pain therapy dissatisfaction before consulting a vertebrologist. The unsatisfactory score proportion on the Likert scale during the treatment in the RFA group decreased to 20.5% (32), and in the pharmacotherapy group – to 28.4% (21), respectively. Conclusion. Pulsed radiofrequency ablation of nerve roots is highly effective and safe, minimally invasive neuromodulatory method for pain treatment in cancer patients with nerve roots compression caused by the spine metastases. This method allows within a short period to reduce or decrease the severity of pain syndrome in 79.5% of patients, contributing to their physical activity increase and improving the quality of life in 77.6% of patients. Pulsed RFA of nerve roots has advantages over conservative treatment in various aspects: decrease in pain syndrome intensity, enhanced patients satisfaction with treatment results, significant pharmacological stress and its associated complications reduction, improved patients physi-cal activity and quality of life.
- 18 December 2024
- Published by Consilium Medicum in Journal of Modern Oncology
- Vol. 26 (4) , 495-503
Open AccessPain relief clinical efficacy using pulsed radiofrequency ablation of nerve roots in patients with spine metastatic lesions. A prospective study
Aim. The objective of the study is to evaluate the clinical efficacy and safety of PRFA (pulsed radiofrequency ablation) of nerve roots in improving general somatic and functional status (Karnofsky score), decreasing pain (NRS) and reducing analgesics consumption (Watkins score) in patients with spine metastatic lesions. Materials and methods. This study involved the analysis of 230 patients with pain syndrome related to metastatic lesions in the spine. Those patients were divided into two groups. The first group included 156 patients who underwent Pulsed RFA of nerve roots in order to relieve pain. There were 69 men and 87 women. The second group, which received only drug treatment with non-opioid and opioid analgesics, consisted of 74 patients, including 30 men and 44 women. The performance status was evaluated with the Karnofsky score (%), pain degree was assessed with the Numerical Rating Scale from 0 to 10 (NRS), and analgesics consumption reduction was assessed by the Watkins scale. Overall treatment satisfaction in patients and physicians was evaluated with the Likert scale. Results. In the pulsed RFA group, 124 (79.5%) patients out of 156 had effective therapy in the form of NRS decrease of at least 50% and at least 1 point decrease by the Watkins scale. The performance status improved by at least 10% according to the Karnofsky index in 121 (77.6%) patients. As for the control group, the effectiveness of pharmacotherapy based on NRS was achieved in 65 (87.8%) out of 74 patients, and the general somatic status was improved in 60 (81.1%) patients. The maximum analgesic effect of the nerve root RFA is achieved on the 10th day after the procedure, maintaining for up to 90 days without dynamics. The level of statistical significance was p0.001. In the RFA group, 153 (98.01%) patients experienced no complications, and in the control group, complications were seen in 64 (86.5%) cases, manifested themselves in the form of adverse events from analgesics used for pain control. Originally, prior to the study, all 100% of patients in both groups expressed pain therapy dissatisfaction before consulting a vertebrologist. The unsatisfactory score proportion on the Likert scale during the treatment in the RFA group decreased to 20.5% (32), and in the pharmacotherapy group – to 28.4% (21), respectively. Conclusion. Pulsed radiofrequency ablation of nerve roots is highly effective and safe, minimally invasive neuromodulatory method for pain treatment in cancer patients with nerve roots compression caused by the spine metastases. This method allows within a short period to reduce or decrease the severity of pain syndrome in 79.5% of patients, contributing to their physical activity increase and improving the quality of life in 77.6% of patients. Pulsed RFA of nerve roots has advantages over conservative treatment in various aspects: decrease in pain syndrome intensity, enhanced patients satisfaction with treatment results, significant pharmacological stress and its associated complications reduction, improved patients physi-cal activity and quality of life.
- Open Access
- 23 June 2024
- Published by Publishing House ABV Press in Bone and soft tissue sarcomas, tumors of the skin
- Vol. 16 (2) , 23-31
The Effectiveness of Radiofrequency Thermal Ablation in the Treatment of Patients with Osteoid Osteomas of the Spine
Osteoid osteoma is a rare benign osteogenic bone tumor without malignant potential causing severe night pain relieved by nonsteroidal anti-inflammatory drugs. Pain associated with osteoid osteoma of the spine cannot be treated conservatively and requires surgical approach. Types of surgical treatment include intralesional curettage, marginal resection, or en bloc tumor resection. However, absence of clear intraoperative visualization of the lesion often leads to excessive resection of vertebral structures requiring additional bone reconstruction and fixation with metal structures. In some cases, due to incorrect choice of resection area and segment level, repeat surgeries are performed causing secondary spinal deformations, worsening patient’s condition, and increasing economic expenditures. Currently, minimally invasive methods of transcutaneous treatment of osteoid osteomas such as interstitial laser ablation, cryotherapy, and radiofrequency thermal ablation are becoming more prominent.Aim. To evaluate the effectiveness of radiofrequency thermal ablation treatment in patients with osteoid osteoma.Materials and methods. The prospective study included 12 patients with osteoid osteoma of the spine. Their quality of life was evaluated using the Short Form-36 (SF-36) questionnaire prior to radiofrequency thermal ablation and 30, 90 and 180 days after. At the first visit and during observation, pain syndrome intensity was measured using the Visual Analog Scale (VAS) and R.G. Watkins scale for objective evaluation of pain syndrome per number of analgesics administrations.Results. Follow-up duration varied between 12 and 36 months. In all clinical cases, general, physical, and psychological health improved 2–3-fold. Pain intensity at day 1 after radiofrequency thermal ablation compared to mean pain intensity during the day prior to the procedure was significantly lower (р = 0.05). At the final examination, none of the patients had pain (pain syndrome intensity 0 per VAS); all patients had subjective satisfaction level of 100 %. Analgesics (nonsteroidal anti-inflammatory drugs and paracetamol) were administered on request for 8 ± 2.34 days after the procedure.Conclusion. Based on literature data and our own experience of diagnosis and surgical treatment of osteoid osteoma of the spine, we conclude that in cases of small lesions (2 cm) in hard to access locations, computed tomography-controlled radiofrequency thermal ablation allows to perform surgical intervention safely, effectively and with minimal number of complications.
- 23 June 2024
- Published by Publishing House ABV Press in Bone and soft tissue sarcomas, tumors of the skin
- Vol. 16 (2) , 23-31
Open AccessThe Effectiveness of Radiofrequency Thermal Ablation in the Treatment of Patients with Osteoid Osteomas of the Spine
Osteoid osteoma is a rare benign osteogenic bone tumor without malignant potential causing severe night pain relieved by nonsteroidal anti-inflammatory drugs. Pain associated with osteoid osteoma of the spine cannot be treated conservatively and requires surgical approach. Types of surgical treatment include intralesional curettage, marginal resection, or en bloc tumor resection. However, absence of clear intraoperative visualization of the lesion often leads to excessive resection of vertebral structures requiring additional bone reconstruction and fixation with metal structures. In some cases, due to incorrect choice of resection area and segment level, repeat surgeries are performed causing secondary spinal deformations, worsening patient’s condition, and increasing economic expenditures. Currently, minimally invasive methods of transcutaneous treatment of osteoid osteomas such as interstitial laser ablation, cryotherapy, and radiofrequency thermal ablation are becoming more prominent.Aim. To evaluate the effectiveness of radiofrequency thermal ablation treatment in patients with osteoid osteoma.Materials and methods. The prospective study included 12 patients with osteoid osteoma of the spine. Their quality of life was evaluated using the Short Form-36 (SF-36) questionnaire prior to radiofrequency thermal ablation and 30, 90 and 180 days after. At the first visit and during observation, pain syndrome intensity was measured using the Visual Analog Scale (VAS) and R.G. Watkins scale for objective evaluation of pain syndrome per number of analgesics administrations.Results. Follow-up duration varied between 12 and 36 months. In all clinical cases, general, physical, and psychological health improved 2–3-fold. Pain intensity at day 1 after radiofrequency thermal ablation compared to mean pain intensity during the day prior to the procedure was significantly lower (р = 0.05). At the final examination, none of the patients had pain (pain syndrome intensity 0 per VAS); all patients had subjective satisfaction level of 100 %. Analgesics (nonsteroidal anti-inflammatory drugs and paracetamol) were administered on request for 8 ± 2.34 days after the procedure.Conclusion. Based on literature data and our own experience of diagnosis and surgical treatment of osteoid osteoma of the spine, we conclude that in cases of small lesions (2 cm) in hard to access locations, computed tomography-controlled radiofrequency thermal ablation allows to perform surgical intervention safely, effectively and with minimal number of complications.
- Open Access
- 8 April 2024
- Published by Publishing House ABV Press in Bone and soft tissue sarcomas, tumors of the skin
- Vol. 16 (1) , 64-75
Validation of the Russian version of Spine Oncology Study Group Outcomes Questionnaire
Introduction. Surgical intervention is the only or main component of combination treatment of the majority of malignant tumors of the spine. Pronounced pain syndrome and neurological deficit caused by spinal tumors significantly worsen disease progression, decrease patients’ quality of life.Aim. To develop a Russian-language version of a specialized questionnaire to study the quality of life of patients suffering from tumor lesions of the spine Spine Oncology Study Group Outcomes Questionnaire (SOSG-OQ).Materials and methods. In 82 patients with tumors of various parts of the spine who are treated at the N.N. Blokhin National Medical Research Center of Oncology, psychometric evaluation of the SOSG-OQ questionnaire was performed confirming its convergent validity and reliability–consistency (Cronbach’s α = 0.899).Results. Exploratory factor analysis confirmed adequacy of the questionnaire’s structure and its conformity to the basic factor model. Instruments of the validated Russian version of the SOSG-OQ questionnaire (text and data analysis instructions) for its use in clinical practice are presented. Results obtained using the new SOSG-OQ questionnaire show a significant decrease in quality of life of patients with spinal tumors. Additionally, after surgery patients described their health-related quality of life significantly higher than prior to treatment.Conclusion. Validated Russian version of the SOSG-OQ questionnaire can be recommended for application in oncological clinic for more precise and differentiated evaluation of performance status, emotional condition, experience of patients, evaluation of life circumstances associated with the disease to promote more targeted and personalized psychological care.
- 8 April 2024
- Published by Publishing House ABV Press in Bone and soft tissue sarcomas, tumors of the skin
- Vol. 16 (1) , 64-75
Open AccessValidation of the Russian version of Spine Oncology Study Group Outcomes Questionnaire
Introduction. Surgical intervention is the only or main component of combination treatment of the majority of malignant tumors of the spine. Pronounced pain syndrome and neurological deficit caused by spinal tumors significantly worsen disease progression, decrease patients’ quality of life.Aim. To develop a Russian-language version of a specialized questionnaire to study the quality of life of patients suffering from tumor lesions of the spine Spine Oncology Study Group Outcomes Questionnaire (SOSG-OQ).Materials and methods. In 82 patients with tumors of various parts of the spine who are treated at the N.N. Blokhin National Medical Research Center of Oncology, psychometric evaluation of the SOSG-OQ questionnaire was performed confirming its convergent validity and reliability–consistency (Cronbach’s α = 0.899).Results. Exploratory factor analysis confirmed adequacy of the questionnaire’s structure and its conformity to the basic factor model. Instruments of the validated Russian version of the SOSG-OQ questionnaire (text and data analysis instructions) for its use in clinical practice are presented. Results obtained using the new SOSG-OQ questionnaire show a significant decrease in quality of life of patients with spinal tumors. Additionally, after surgery patients described their health-related quality of life significantly higher than prior to treatment.Conclusion. Validated Russian version of the SOSG-OQ questionnaire can be recommended for application in oncological clinic for more precise and differentiated evaluation of performance status, emotional condition, experience of patients, evaluation of life circumstances associated with the disease to promote more targeted and personalized psychological care.
- Open Access
- 1 July 2023
- Published by Publishing House ABV Press in Bone and soft tissue sarcomas, tumors of the skin
- Vol. 15 (2) , 46-52
Hibernoma: a case report and discussion of a rare tumor
Intriduction. Hibernomas account for less than 2 % of all benign lipomatous tumors and 1 % of all lipomatous tumors. They are usually found in 20–40-year old adults (the average age of patients is 38 years). The clinical manifestations are painless soft tissue mass that are mostly slow growing; rapid growth is only found in a small number of patients. We present a case of successful surgical treatment of a pathologically confirmed rare lipomatous tumor of large size, which was located in the soft tissues of the thigh.Clinical case. A 46-year-old woman was admitted to the hospital due to a tumor 20 × 10 × 10 cm in size, that had developed 10 years ago in the anteromedial aspect of the proximal thigh. Furthermore, she had a history of hypoesthesia one month prior to her admission. During surgery, the femoral nerve was found to be compressed by the large tumor. The resultant symptoms probably caused the patient to seek medical care. Resection was performed by careful dissection, femoral nerve and vessels were spared. Histopathological examination and cytogenetics showed findings suggestive of a hibernoma. At the 6-month follow-up local tumor recurrence or metastasis was not found.Conclusions. Asymptomatic small-sized hibernoma does not require surgical resection or other treatment. When the tumor is too large and/or has the potential to compress the surrounding tissues, timely radical surgical intervention is reuired.
- 1 July 2023
- Published by Publishing House ABV Press in Bone and soft tissue sarcomas, tumors of the skin
- Vol. 15 (2) , 46-52
Open AccessHibernoma: a case report and discussion of a rare tumor
Intriduction. Hibernomas account for less than 2 % of all benign lipomatous tumors and 1 % of all lipomatous tumors. They are usually found in 20–40-year old adults (the average age of patients is 38 years). The clinical manifestations are painless soft tissue mass that are mostly slow growing; rapid growth is only found in a small number of patients. We present a case of successful surgical treatment of a pathologically confirmed rare lipomatous tumor of large size, which was located in the soft tissues of the thigh.Clinical case. A 46-year-old woman was admitted to the hospital due to a tumor 20 × 10 × 10 cm in size, that had developed 10 years ago in the anteromedial aspect of the proximal thigh. Furthermore, she had a history of hypoesthesia one month prior to her admission. During surgery, the femoral nerve was found to be compressed by the large tumor. The resultant symptoms probably caused the patient to seek medical care. Resection was performed by careful dissection, femoral nerve and vessels were spared. Histopathological examination and cytogenetics showed findings suggestive of a hibernoma. At the 6-month follow-up local tumor recurrence or metastasis was not found.Conclusions. Asymptomatic small-sized hibernoma does not require surgical resection or other treatment. When the tumor is too large and/or has the potential to compress the surrounding tissues, timely radical surgical intervention is reuired.
- Open Access
- 15 May 2023
- Published by Publishing House ABV Press in Advances in molecular oncology
- Vol. 10 (2) , 100-107
The content of sEMMPRIN/CD147 in the blood serum of patients with bone tumors and its relationship with the clinical and morphological characteristics of the disease
Introduction. Enzyme-linked immunosorbent assay of biochemical markers is one of the most important methods for diagnosing tumors. One of these markers is an inducer of expression of matrix metalloproteases EMMPRIN/CD147. Changes in its expression are associated with the progression of some tumors. This study is the first work devoted to the study of the content of the soluble form of the transmembrane glycoprotein EMMPRIN (sEMMPRIN) in the blood serum of patients with various bone tumors.Aim. To study the content of sEMMPRIN in the blood serum of patients with malignant bone tumors, its relationship with the clinical and morphological characteristics of neoplasms and prognosis.Materials and methods. The study included 88 patients with malignant tumors (osteosarcoma – 37 cases, chondrosarcoma – 39, chordoma – 5, Ewing’s sarcoma – 7) and borderline (11 cases) bone neoplasms, of which 14 patients were under the age of 18 years. The control group consisted of 29 healthy donors, 8 of which were under the age of 18 years. The concentration of EMMPRIN was determined in the serum of patients and donors with reagents for direct enzyme immunoassay “Human EMMPRIN” (RD, USA) in accordance with the manufacturer’s instructions and expressed in nanograms (ng) per 1 ml of blood serum. The obtained data were processed using the GraphPad Prizm 9.4 program. When comparing indicators and analyzing their relationships, we used the nonparametric Mann–Whitney and Kruskal–Wallis tests. Overall survival was analyzed using the Kaplan–Meier method.Results. Our analysis of the sEMMPRIN content in the blood serum of patients with bone tumors did not reveal statistically significant differences between the control group and patients with borderline and malignant tumors, both in adults and in children. At the same time, a trend towards a decrease in the level of sEMMPRIN in the blood serum was noted in the presence of a malignant neoplasm of the bone compared with the corresponding control group. Additionally, we found that the content of sEMMPRIN is associated with age and higher in the group of patients under 18 years of age, both among healthy donors and oncological patients. An analysis of the association of sEMMPRIN content with clinical and morphological characteristics did not reveal statistically significant patterns, however, a trend towards an increase in the level of the marker with disease progression in both studied age groups was observed, which is consistent with other studies conducted on other solid tumors.Conclusion. ELISA revealed the marker sEMMPRIN in the blood serum of all examined children and adults with borderline malignant bone tumors and healthy donors. At the same time, the levels of sEMMPRIN did not differ between the above groups, however, there was a tendency for a decrease in the concentration of the marker in patients with bone sarcomas compared with the control group, regardless of age.
- 15 May 2023
- Published by Publishing House ABV Press in Advances in molecular oncology
- Vol. 10 (2) , 100-107
Open AccessThe content of sEMMPRIN/CD147 in the blood serum of patients with bone tumors and its relationship with the clinical and morphological characteristics of the disease
Introduction. Enzyme-linked immunosorbent assay of biochemical markers is one of the most important methods for diagnosing tumors. One of these markers is an inducer of expression of matrix metalloproteases EMMPRIN/CD147. Changes in its expression are associated with the progression of some tumors. This study is the first work devoted to the study of the content of the soluble form of the transmembrane glycoprotein EMMPRIN (sEMMPRIN) in the blood serum of patients with various bone tumors.Aim. To study the content of sEMMPRIN in the blood serum of patients with malignant bone tumors, its relationship with the clinical and morphological characteristics of neoplasms and prognosis.Materials and methods. The study included 88 patients with malignant tumors (osteosarcoma – 37 cases, chondrosarcoma – 39, chordoma – 5, Ewing’s sarcoma – 7) and borderline (11 cases) bone neoplasms, of which 14 patients were under the age of 18 years. The control group consisted of 29 healthy donors, 8 of which were under the age of 18 years. The concentration of EMMPRIN was determined in the serum of patients and donors with reagents for direct enzyme immunoassay “Human EMMPRIN” (RD, USA) in accordance with the manufacturer’s instructions and expressed in nanograms (ng) per 1 ml of blood serum. The obtained data were processed using the GraphPad Prizm 9.4 program. When comparing indicators and analyzing their relationships, we used the nonparametric Mann–Whitney and Kruskal–Wallis tests. Overall survival was analyzed using the Kaplan–Meier method.Results. Our analysis of the sEMMPRIN content in the blood serum of patients with bone tumors did not reveal statistically significant differences between the control group and patients with borderline and malignant tumors, both in adults and in children. At the same time, a trend towards a decrease in the level of sEMMPRIN in the blood serum was noted in the presence of a malignant neoplasm of the bone compared with the corresponding control group. Additionally, we found that the content of sEMMPRIN is associated with age and higher in the group of patients under 18 years of age, both among healthy donors and oncological patients. An analysis of the association of sEMMPRIN content with clinical and morphological characteristics did not reveal statistically significant patterns, however, a trend towards an increase in the level of the marker with disease progression in both studied age groups was observed, which is consistent with other studies conducted on other solid tumors.Conclusion. ELISA revealed the marker sEMMPRIN in the blood serum of all examined children and adults with borderline malignant bone tumors and healthy donors. At the same time, the levels of sEMMPRIN did not differ between the above groups, however, there was a tendency for a decrease in the concentration of the marker in patients with bone sarcomas compared with the control group, regardless of age.
- Open Access
- 22 April 2023
- Published by Publishing House ABV Press in Bone and soft tissue sarcomas, tumors of the skin
- Vol. 15 (1) , 57-65
Safety and effectiveness of continuous denosumab for unresectable or advanced giant cell tumor
Introduction. Giant cell tumor of bone is a relatively rare, locally aggressive osteolytic skeletal neoplasm with uncertain behavior: recurrence rates up to 70 % and distant metastases occur 2–6 % of cases. Nowadays denosumab is the choice of therapy for patients with unresectable or advanced disease. However, the efficiency, duration or administration and most of all safety of continuous denosumab are not established.Materials and methods. Fourty advanced or unresectable giant cell tumor cases were observed from 2005 till 2020 in N.N. Blokhin National Medical Research Center of Oncology. The average age of pts was 33,6 ± 13,1 years (18–64), and the women and men ratio was about 2,1 : 1. The most commonly affected sites were long bones of the lower extremities (22,5 %), sacrum (22,5 %), long bones of the upper extremities (17,5 %), spine (17,5 %), pelvis (10 %) and others. 70 % of cases were anatomically compounded due to tumor localization and 27,5 % of cases were primary disease. 37,5 % of cases were with pulmonary metastases. Patients underwent computed tomography / magnetic resonance imaging every 3 months during the first three years and then once every six months. Patient received subcutaneous denosumab 120 mg every 4 weeks with a loading dose of 120 mg subcutaneous on study days 8 and 15. After 2 years monthly therapy and confirmed stabilization effect patient then received maintenance therapy: once in three months injection. All patients received daily calcium and vitamin D supplement.Results. Median follow-up was 52,8 ± 41,3 months (3–219 months). The average denosumab injections were 25 ± 16 (4–85). Clinical and radiographically stabilization of the effect occurred on average at 12 ± 8 (4–32) injections. Hypocalcemia was registered in one case (2.5 %). There was significant improvement of Karnofsky scale, Visual analogue scale (VAS) and Watkins scale (p 0.001). 5-year progression-free survival for was 70.1 % (95 % confidence interval 55.7–88.0), the median was not reached. Progression of disease was observed only in subgroup with violations in denosumab administration or its cancellation (32,5 %). 3-year progression-free survival in subgroup with violations in denosumab administration or its cancellation was 10 % (95 % confidence interval 15.5–64.1). In subgroup with continuous denosumab and once in three months injection after 2 years monthly therapy there was no signs of progression.Conclusions. In this study we showed evidence of safety and effectiveness of continuous denosumab for unresectable or advanced giant cell tumor even with once in three months injection therapy. Denosumab for advanced giant cell tumor of bone became a choice of treatment, but we need further investigation for observation long term denosumab effectiveness and complications.
- 22 April 2023
- Published by Publishing House ABV Press in Bone and soft tissue sarcomas, tumors of the skin
- Vol. 15 (1) , 57-65
Open AccessSafety and effectiveness of continuous denosumab for unresectable or advanced giant cell tumor
Introduction. Giant cell tumor of bone is a relatively rare, locally aggressive osteolytic skeletal neoplasm with uncertain behavior: recurrence rates up to 70 % and distant metastases occur 2–6 % of cases. Nowadays denosumab is the choice of therapy for patients with unresectable or advanced disease. However, the efficiency, duration or administration and most of all safety of continuous denosumab are not established.Materials and methods. Fourty advanced or unresectable giant cell tumor cases were observed from 2005 till 2020 in N.N. Blokhin National Medical Research Center of Oncology. The average age of pts was 33,6 ± 13,1 years (18–64), and the women and men ratio was about 2,1 : 1. The most commonly affected sites were long bones of the lower extremities (22,5 %), sacrum (22,5 %), long bones of the upper extremities (17,5 %), spine (17,5 %), pelvis (10 %) and others. 70 % of cases were anatomically compounded due to tumor localization and 27,5 % of cases were primary disease. 37,5 % of cases were with pulmonary metastases. Patients underwent computed tomography / magnetic resonance imaging every 3 months during the first three years and then once every six months. Patient received subcutaneous denosumab 120 mg every 4 weeks with a loading dose of 120 mg subcutaneous on study days 8 and 15. After 2 years monthly therapy and confirmed stabilization effect patient then received maintenance therapy: once in three months injection. All patients received daily calcium and vitamin D supplement.Results. Median follow-up was 52,8 ± 41,3 months (3–219 months). The average denosumab injections were 25 ± 16 (4–85). Clinical and radiographically stabilization of the effect occurred on average at 12 ± 8 (4–32) injections. Hypocalcemia was registered in one case (2.5 %). There was significant improvement of Karnofsky scale, Visual analogue scale (VAS) and Watkins scale (p 0.001). 5-year progression-free survival for was 70.1 % (95 % confidence interval 55.7–88.0), the median was not reached. Progression of disease was observed only in subgroup with violations in denosumab administration or its cancellation (32,5 %). 3-year progression-free survival in subgroup with violations in denosumab administration or its cancellation was 10 % (95 % confidence interval 15.5–64.1). In subgroup with continuous denosumab and once in three months injection after 2 years monthly therapy there was no signs of progression.Conclusions. In this study we showed evidence of safety and effectiveness of continuous denosumab for unresectable or advanced giant cell tumor even with once in three months injection therapy. Denosumab for advanced giant cell tumor of bone became a choice of treatment, but we need further investigation for observation long term denosumab effectiveness and complications.
- Open Access
- 23 December 2021
- Published by Association of Spine Surgeons in Russian Journal of Spine Surgery (Khirurgiya Pozvonochnika)
- Vol. 18 (4) , 81-90
The role of denosumab in the complex treatment of giant cell tumor of the spine: reducing of local recurrence rate, surgery time and blood loss
Objective. To assess the effect of the combined treatment method including preoperative denosumab therapy on the results of treatment of patients with giant cell tumors of the spine.Material and Methods. A single-center retrospective-prospective study of a series of clinical cases included 15 patients with giant cell tumors of vertebrae. The average follow-up period was 56 months. A total of 11 patients received denosumab therapy according to the following scheme: 120 mg subcutaneously on the 1st, 8th, 15th and 28th days of the first month and then once every 28 days. Surgical options included marginal resection, segmental resection, or en-bloc resection with or without spinal reconstruction/stabilization. In the case of locally advanced and inoperable disease, long-term therapy with denosumab was carried out until the disease progressed or serious adverse events appeared.Results. Thoracic vertebrae were involved in 7 (46.6 %) of 15 cases, lumbar in 4 (26.7 %) and cervical in 4 (26.7 %). Local recurrence rate after surgery alone was 40 % (2/5), average time to recurrence onset was 4.5 months. No relapses were observed after combined treatment performed in four patients. Disease progression during long-term denosumab therapy for inoperable disease recurrence was not recorded (0/7). The average number of denosumab injections before surgery and during long-term therapy was 15 and 24 injections, respectively. Denosumab therapy allows reducing the duration of surgery and the volume of blood loss.Conclusion. Combined therapy of giant cell vertebral tumor allows to reduce the risk of recurrence of the disease, as well as to reduce surgery duration and blood loss. Long-term continuous therapy for inoperable cases allows achieving long-term stabilization of the effect. Due to the rarity of giant cell tumors of the spine, a further prospective recruitment of patients is required to study the efficacy and safety of combined therapies.
- 23 December 2021
- Published by Association of Spine Surgeons in Russian Journal of Spine Surgery (Khirurgiya Pozvonochnika)
- Vol. 18 (4) , 81-90
Open AccessThe role of denosumab in the complex treatment of giant cell tumor of the spine: reducing of local recurrence rate, surgery time and blood loss
Objective. To assess the effect of the combined treatment method including preoperative denosumab therapy on the results of treatment of patients with giant cell tumors of the spine.Material and Methods. A single-center retrospective-prospective study of a series of clinical cases included 15 patients with giant cell tumors of vertebrae. The average follow-up period was 56 months. A total of 11 patients received denosumab therapy according to the following scheme: 120 mg subcutaneously on the 1st, 8th, 15th and 28th days of the first month and then once every 28 days. Surgical options included marginal resection, segmental resection, or en-bloc resection with or without spinal reconstruction/stabilization. In the case of locally advanced and inoperable disease, long-term therapy with denosumab was carried out until the disease progressed or serious adverse events appeared.Results. Thoracic vertebrae were involved in 7 (46.6 %) of 15 cases, lumbar in 4 (26.7 %) and cervical in 4 (26.7 %). Local recurrence rate after surgery alone was 40 % (2/5), average time to recurrence onset was 4.5 months. No relapses were observed after combined treatment performed in four patients. Disease progression during long-term denosumab therapy for inoperable disease recurrence was not recorded (0/7). The average number of denosumab injections before surgery and during long-term therapy was 15 and 24 injections, respectively. Denosumab therapy allows reducing the duration of surgery and the volume of blood loss.Conclusion. Combined therapy of giant cell vertebral tumor allows to reduce the risk of recurrence of the disease, as well as to reduce surgery duration and blood loss. Long-term continuous therapy for inoperable cases allows achieving long-term stabilization of the effect. Due to the rarity of giant cell tumors of the spine, a further prospective recruitment of patients is required to study the efficacy and safety of combined therapies.